Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Assessing Candidacy for Long-Acting ART

Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares the latest data about which patient factors may predict failure to LA CAB plus RPV and who is and who is not a good candidate for this new treatment option.
person default
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Released: December 16, 2021

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on patient specific factors associated with LA CAB plus RPV failure.

Listen as she gives her perspectives on:

  • LA CAB plus RPV pharmacokinetic data
  • DHHS guideline recommendations on which patients can be considered for LA CAB plus RPV
  • Data from the ATLAS, FLAIR, and ATLAS-2M studies on patients with virologic failure and the factors that may have contributed

Information on this Educational Activity

Faculty

Milena Murray, PharmD, MSc, BCIDP, AAHIVP

Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Pharmacy
Northwestern Memorial Hospital
Chicago, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings